Gosebruch provided an update on Galapagos’s legacy R&D asset, the TYK2 inhibitor GLPG3667. He noted that the company announced top-line Phase 2 results in December for studies in dermatomyositis and systemic lupus erythematosus (SLE). According to management, GLPG3667 met the primary endpoint in dermatomyositis, showing a statistically significant clinical benefit and improvements on secondary measures versus placebo.Gosebruch said Galapagos is “aggressively evaluating opportunities” across its focus areas ...

Market Overview - U.S. stock futures showed mixed results following a higher close on Monday, with the Dow Jones increasing nearly 600 points to a new all-time high after the capture of Venezuelan President Nicolás Maduro [1] - The 10-year Treasury bond yielded 4.17%, while the two-year bond was at 3.45%, with an 83.9% likelihood of the Federal Reserve maintaining current interest rates in January [2] Stocks in Focus - CoreWeave Inc. (NASDAQ:CRWV) shares rose 1.87% as it plans to integrate Nvidia Corp.'s Rubin platform into its cloud services, although it maintains a weaker price trend overall [5] - Vistra Corp. (NYSE:VST) shares increased by 4.13% after acquiring Cogentrix Energy for approximately $4.7 billion, but it also has a weaker price trend [5] - Microchip Technology Inc. (NASDAQ:MCHP) advanced 3.19% after projecting third-quarter fiscal 2026 net sales of about $1.185 billion, exceeding previous guidance [5] - Galapagos NV ADR (NASDAQ:GLPG) shares climbed 5.99% following the decision to wind down its cell therapy activities, maintaining a stronger price trend [5] Analyst Insights - Professor Jeremy Siegel expressed a positive outlook for 2026, citing strong GDP tracking and resilient holiday spending, indicating a fundamentally solid market [9] - Siegel noted that higher productivity is disinflationary, allowing for real growth without necessitating Federal Reserve policy tightening, and suggested the Fed could cut rates by 50 basis points by mid-year [10] - Despite potential risks in January, Siegel believes the underlying fundamentals favor a positive investing environment for 2026 [11]

Core Viewpoint - U.S. stock futures are trading higher, with several companies expected to report earnings and revenue figures that may attract investor attention [1] Company Summaries - **AngioDynamics, Inc. (NASDAQ:ANGO)**: Expected to report a quarterly loss of $0.10 per share on revenue of $76.30 million. Shares decreased by 0.2% to $13.20 in after-hours trading [1] - **Microchip Technology Inc (NASDAQ:MCHP)**: Anticipates third-quarter fiscal 2026 net sales of approximately $1.185 billion, exceeding previous guidance of $1.109 billion to $1.149 billion. Shares increased by 3.2% to $69.20 in after-hours trading [1] - **AAR Corp (NYSE:AIR)**: Analysts expect quarterly earnings of $1.04 per share on revenue of $761.13 million, with earnings to be released after market close. Shares rose by 0.8% to $88.70 in after-hours trading [1] - **Galapagos NV – ADR (NASDAQ:GLPG)**: The board has decided to wind down the company's cell therapy activities after a strategic review. Shares increased by 6% to $34.70 in after-hours trading [1] - **Penguin Solutions Inc. (NASDAQ:PENG)**: Expected to report quarterly earnings of $0.44 per share on revenue of $338.76 million after market close. Shares rose by 0.6% to $21.19 in after-hours trading [1]

Core Insights - The gene therapy (CGT) sector is experiencing a significant decline in venture capital investment, with deals dropping by approximately 61% from 2021 to 2025, and CGT-specific deals decreasing by 66% in the same timeframe [1][2] Industry Trends - Half of the CGT venture capital activity is concentrated in Series B funding, indicating a shift from platform validation to clinical studies, reflecting a broader trend in the pharmaceutical industry towards less risky targets like obesity drugs and antibody-drug conjugates (ADCs) [2] - The average value of CGT venture capital deals is currently around $60 million in 2025, which is notably lower compared to other modalities, highlighting a decrease in deal frequency and value [3] Market Dynamics - The peak activity for venture capital in the CGT sector occurred in 2021, but commercial challenges have led some companies to withdraw from the space despite the presence of approved CGT therapies in major markets like the US and Europe [4] - Companies such as Galapagos and Takeda have recently exited the cell therapy sector, indicating a shift in focus towards small molecules, biologics, and ADCs [5] Acquisition Strategies - There is ongoing interest from biopharma companies in CGT technologies, primarily through acquisitions rather than in-house development, with a focus on platforms and scalable manufacturing systems [6] - Eli Lilly has been notably active in the CGT space, investing $475 million in a licensing deal for ophthalmology gene therapy and acquiring Adverum Biotechnologies for over $260 million, along with a $1.3 billion investment in Rznomics for RNA-based gene therapies [6]

Core Insights - Galapagos NV announced promising Phase 2 data for GLPG5101, a CAR T-cell therapy for high-risk mantle cell lymphoma (MCL), showing high complete response rates and minimal residual disease negativity with durable responses [1][5] Group 1: Study Results - The ATALANTA-1 study reported an objective response rate (ORR) of 100% and a complete response rate (CRR) of 96% among infused patients [5] - At a median follow-up of 9 months, both duration of response (DOR) and progression-free survival (PFS) rates were 83% [5] - Among minimal residual disease (MRD)-evaluated patients, 90% were MRD-negative at complete response, with 7 out of 9 MRD-negative patients remaining in complete response at the data cut-off [5] Group 2: Safety Profile - GLPG5101 demonstrated a favorable safety profile, with the most common Grade ≥ 3 treatment-emergent adverse events being hematologic [5] - No Grade ≥ 3 cytokine release syndrome (CRS) was observed, and only one case of Grade ≥ 3 immune effector cell-associated neurotoxicity syndrome (ICANS) occurred [5] Group 3: Manufacturing and Administration - GLPG5101 is a second-generation anti-CD19/4-1BB CAR-T product administered as a single fixed intravenous dose, with a 7-day vein-to-vein time [1][4] - The study evaluated three dose levels: 50×10^6, 110×10^6, and 250×10^6 CAR+ viable T-cells [4] - The low dropout rate of 4% and elimination of the need for bridging therapy allowed more patients to access treatment [1][2] Group 4: Company Strategy - Galapagos intends to wind down its cell therapy activities while continuing to operate the business and conduct ongoing clinical studies [3] - The company remains open to viable proposals for acquiring all or part of its cell therapy business during the wind-down process [3]

Financial Data and Key Metrics Changes - The company raised $219 million in its IPO in February 2025, providing financial flexibility to execute its strategy through 2028 [7] - As of Q3, the company reported having $325 million in cash, ensuring a cash runway into 2028 [46] Business Line Data and Key Metrics Changes - The company is focused on developing two NBD1 stabilizers: SION-719 for an add-on approach to the standard of care and SION-451 for a dual combination strategy [5][6] - The company aims to demonstrate a clinically meaningful improvement of at least 10 millimoles per liter in sweat chloride, which is expected to correlate with a 3-point improvement in FEV1 [34][35] Market Data and Key Metrics Changes - The cystic fibrosis market is currently valued at $12 billion and is projected to grow to $15 billion [12] - The company targets the same patient population as the standard of care, focusing on the F508del mutation, which affects 85%-90% of cystic fibrosis patients [19] Company Strategy and Development Direction - The company aims to transform the standard of care in cystic fibrosis by focusing on the NBD1 target, which has been historically considered undruggable [4][10] - The dual combination strategy is prioritized, with the goal of raising the efficacy bar through innovative combinations of therapies [6][12] Management's Comments on Operating Environment and Future Outlook - Management believes that there is a significant unmet need in the cystic fibrosis community, as two-thirds of patients on standard care do not achieve normal CFTR function [16] - The company is optimistic about its clinical development strategy and the potential to improve patient outcomes significantly [70] Other Important Information - The company has licensed three compounds from AbbVie, enhancing its portfolio with clinical data and complementary mechanisms [41][42] - The Therapeutics Development Network (TDN) of the Cystic Fibrosis Foundation is a key partner, providing access to a well-organized research network [65][66] Q&A Session Summary Question: What is the company's strategy for addressing the unmet needs in cystic fibrosis? - The company aims to improve CFTR function in patients who are currently on standard care but do not achieve normal function, focusing on the NBD1 stabilization approach [16][19] Question: How does the company plan to differentiate its products in the market? - The company plans to leverage its unique dual combination strategy and the historical data from its assays to demonstrate improved efficacy compared to existing therapies [6][70] Question: What are the expected timelines for clinical data? - The company anticipates data from its phase 2a proof of concept study in mid-2026, which will be crucial for informing future development and capital raising decisions [5][29]

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Core Insights - The article discusses the presentation of new Phase 2 data for GLPG5101, a CAR-T cell therapy candidate by Galapagos, at the upcoming ASH Annual Meeting, highlighting its potential in treating high-risk relapsed/refractory mantle cell lymphoma and large B-cell lymphoma [1][2][3] Group 1: Clinical Data Presentation - Two abstracts will present new Phase 2 data for GLPG5101 in relapsed/refractory mantle cell lymphoma (R/R MCL) and large B-cell lymphoma (R/R DLBCL) [2] - The oral presentation will showcase high complete response rates and minimal residual disease negativity, with low rates of severe grade toxicities, demonstrating the therapy's effectiveness [5][6] - The data supports the hypothesis that rapid delivery of fresh, early-memory enriched CAR-T cells can improve patient outcomes [3][5] Group 2: Manufacturing and Administration - GLPG5101 is manufactured using an innovative platform that allows for a median vein-to-vein time of seven days, facilitating broader access to cell therapy [1][9] - The manufacturing process includes a decentralized, automated system that enhances the quality control and patient experience [9] - The therapy is administered as a single fixed intravenous dose, with ongoing evaluations of safety and efficacy in the ATALANTA-1 study [8][9] Group 3: Company Showcase and Future Directions - Galapagos will host a company showcase titled "Fast, Fresh, Fit," focusing on the transformative potential of their cell therapy approach [2] - The ATALANTA-1 study is currently enrolling patients in the U.S. and Europe, with a primary objective to evaluate the Objective Response Rate (ORR) [8] - The company is also considering proposals for acquiring its cell therapy business during its ongoing transformation [13]

Core Viewpoint - Evaxion A/S has appointed Dr. Helen Tayton-Martin as the new CEO, effective November 24, 2025, marking a significant leadership change for the company as it continues to develop its AI-Immunology™ powered vaccines [1][4]. Company Leadership - Dr. Helen Tayton-Martin holds a Ph.D. in molecular immunology and an MBA from London Business School, with extensive experience in the biotech sector, including co-founding Adaptimmune and overseeing its growth and strategic partnerships [2][9]. - Birgitte Rønø, who served as interim CEO, will return to her role as Chief Scientific Officer, continuing to lead research and development efforts [5][9]. Board Changes - Dr. Tayton-Martin will step down from Evaxion's Board of Directors upon assuming the CEO role, while Jens Bitsch-Norhave will join the Board as an adviser and observer, with plans to seek election as a board member in 2026 [7][8]. Company Strategy and Potential - Dr. Tayton-Martin expressed excitement about joining Evaxion at a pivotal time, highlighting the company's AI-Immunology platform and recent achievements, such as the out-licensing of EVX-B3 to MSD and promising data for EVX-01 presented at ESMO [6][9]. - Evaxion is focused on developing novel immunotherapies for cancer and infectious diseases, leveraging its AI technology to address high unmet medical needs [11].

Core Viewpoint - Galapagos NV is set to present new in vitro pharmacological data for its selective TYK2 inhibitor, GLPG3667, at the ACR Convergence 2025, highlighting its differentiation from other TYK2 inhibitors in clinical dose regimens [1][2]. Group 1: Study Overview - GLPG3667 is currently being evaluated in two Phase 3-enabling studies for systemic lupus erythematosus (SLE) and dermatomyositis (DM) [5]. - The GALACELA study is a randomized, double-blind, placebo-controlled trial assessing GLPG3667's efficacy and safety in adults with active SLE over 48 weeks [6]. - The GALARISSO study is also a randomized, double-blind, placebo-controlled trial focusing on GLPG3667's efficacy and safety in adults with DM over 24 weeks [9]. Group 2: Key Findings - At the clinical dose of 150 mg once daily, GLPG3667 demonstrated comparable inhibition of the IFN-α and IL-23 pathways to currently approved TYK2 inhibitors, with a more pronounced inhibition of the IL-12 pathway [7]. - GLPG3667 showed no measurable inhibition of IL-10-mediated signaling at concentrations significantly above clinical levels, unlike other TYK2 inhibitors [7]. - The primary endpoint for the GALACELA study is the proportion of patients achieving the SLE responder index (SRI)-4 response at Week 32, with secondary endpoints including various lupus assessment scores [6][8].